$60.50
1.12% yesterday
Nasdaq, Oct 20, 10:04 pm CET
ISIN
US5015751044
Symbol
KYMR

Kymera Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Kymera Therapeutics Inc Classifications & Recommendation:

Buy
96%
Hold
4%

Kymera Therapeutics Inc Price Target

Target Price $61.20
Price $60.50
Potential
Number of Estimates 22
22 Analysts have issued a price target Kymera Therapeutics Inc 2026 . The average Kymera Therapeutics Inc target price is $61.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 27 analysts: 26 Analysts recommend Kymera Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Kymera Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Kymera Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 47.07 76.31
40.11% 62.11%
EBITDA Margin -529.72% -372.79%
157.03% 29.63%
Net Margin -475.59% -322.85%
154.33% 32.12%

23 Analysts have issued a sales forecast Kymera Therapeutics Inc 2025 . The average Kymera Therapeutics Inc sales estimate is

$76.3m
Unlock
. This is
70.67% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$154m 245.18%
Unlock
, the lowest is
$42.7m 4.43%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $47.1m 40.11%
2025
$76.3m 62.11%
Unlock
2026
$56.4m 26.04%
Unlock
2027
$58.8m 4.19%
Unlock
2028
$39.9m 32.10%
Unlock
2029
$69.1m 73.04%
Unlock
2030
$248m 259.50%
Unlock
2031
$526m 111.61%
Unlock
2032
$2.9b 448.16%
Unlock

8 Analysts have issued an Kymera Therapeutics Inc EBITDA forecast 2025. The average Kymera Therapeutics Inc EBITDA estimate is

$-284m
Unlock
. This is
6.35% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-183m 39.62%
Unlock
, the lowest is
$-334m 10.01%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-249m 53.94%
2025
$-284m 14.09%
Unlock
2026
$-367m 29.09%
Unlock
2027
$-434m 18.23%
Unlock

EBITDA Margin

2024 -529.72% 157.03%
2025
-372.79% 29.63%
Unlock
2026
-650.68% 74.54%
Unlock
2027
-738.39% 13.48%
Unlock

23 Kymera Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Kymera Therapeutics Inc net profit estimate is

$-246m
Unlock
. This is
10.56% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-184m 33.29%
Unlock
, the lowest is
$-271m 1.59%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-224m 52.33%
2025
$-246m 10.05%
Unlock
2026
$-294m 19.51%
Unlock
2027
$-313m 6.35%
Unlock
2028
$-340m 8.54%
Unlock
2029
$-308m 9.26%
Unlock
2030
$-197m 36.09%
Unlock
2031
$-85.8m 56.47%
Unlock
2032
$1.1b 1,419.29%
Unlock

Net Margin

2024 -475.59% 154.33%
2025
-322.85% 32.12%
Unlock
2026
-521.70% 61.59%
Unlock
2027
-532.53% 2.08%
Unlock
2028
-851.25% 59.85%
Unlock
2029
-446.39% 47.56%
Unlock
2030
-79.36% 82.22%
Unlock
2031
-16.32% 79.44%
Unlock
2032
39.29% 340.75%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.98 -3.49
18.25% 17.11%
P/E negative
EV/Sales 48.02

23 Analysts have issued a Kymera Therapeutics Inc forecast for earnings per share. The average Kymera Therapeutics Inc EPS is

$-3.49
Unlock
. This is
2.05% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.60 23.98%
Unlock
, the lowest is
$-3.84 12.28%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.98 18.25%
2025
$-3.49 17.11%
Unlock
2026
$-4.17 19.48%
Unlock
2027
$-4.44 6.47%
Unlock
2028
$-4.82 8.56%
Unlock
2029
$-4.37 9.34%
Unlock
2030
$-2.79 36.16%
Unlock
2031
$-1.22 56.27%
Unlock
2032
$16.04 1,414.75%
Unlock

P/E ratio

Current -17.69 16.52%
2025
-17.33 2.04%
Unlock
2026
-14.50 16.33%
Unlock
2027
-13.63 6.00%
Unlock
2028
-12.56 7.85%
Unlock
2029
-13.84 10.19%
Unlock
2030
-21.66 56.50%
Unlock
2031
-49.76 129.73%
Unlock
2032
3.77 107.58%
Unlock

Based on analysts' sales estimates for 2025, the Kymera Therapeutics Inc stock is valued at an EV/Sales of

48.02
Unlock
and an P/S ratio of
56.69
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 81.96 193.87%
2025
48.02 41.41%
Unlock
2026
64.93 35.21%
Unlock
2027
62.32 4.02%
Unlock
2028
91.78 47.27%
Unlock
2029
53.04 42.21%
Unlock
2030
14.75 72.18%
Unlock
2031
6.97 52.74%
Unlock
2032
1.27 81.76%
Unlock

P/S ratio

Current 96.75 183.42%
2025
56.69 41.41%
Unlock
2026
76.65 35.21%
Unlock
2027
73.57 4.02%
Unlock
2028
108.34 47.27%
Unlock
2029
62.61 42.21%
Unlock
2030
17.42 72.18%
Unlock
2031
8.23 52.74%
Unlock
2032
1.50 81.76%
Unlock

Current Kymera Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Citigroup
Locked
Locked
Locked Oct 17 2025
Oppenheimer
Locked
Locked
Locked Oct 01 2025
Truist Securities
Locked
Locked
Locked Sep 30 2025
HC Wainwright & Co.
Locked
Locked
Locked Sep 18 2025
Barclays
Locked
Locked
Locked Sep 17 2025
RBC Capital
Locked
Locked
Locked Sep 16 2025
Oppenheimer
Locked
Locked
Locked Jun 27 2025
Analyst Rating Date
Locked
Citigroup:
Locked
Locked
Oct 17 2025
Locked
Oppenheimer:
Locked
Locked
Oct 01 2025
Locked
Truist Securities:
Locked
Locked
Sep 30 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 18 2025
Locked
Barclays:
Locked
Locked
Sep 17 2025
Locked
RBC Capital:
Locked
Locked
Sep 16 2025
Locked
Oppenheimer:
Locked
Locked
Jun 27 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today